Cell population in spleens during antibody-mediated rejection: Pathologic and clinical findings

Transplantation

Volumn 94, Issue 3, 2012, Pages 255-262

  Tzvetanov, Ivo ^a   Spaggiari, Mario ^a   Oberholzer, Jose ^a   Setty, Suman ^a   Stephenson, Amanda ^a   Thielke, James ^a   West Thielke, Patricia ^a   Jeon, Hoonbae ^a   Danielson, Kirstie K ^a   Kaplan, Bruce ^b   Benedetti, Enrico ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody mediated rejection; Kidney transplantation; Plasma cells; Splenectomy

Indexed keywords

BORTEZOMIB; CD20 ANTIGEN; CD3 ANTIGEN; RITUXIMAB; SYNDECAN 1;

ACUTE ANTIBODY MEDIATED GRAFT REJECTION; ACUTE GRAFT REJECTION; ADULT; B LYMPHOCYTE; CELL COUNT; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DESENSITIZATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PLASMA CELL; PRIORITY JOURNAL; REVIEW; SPLEEN; SPLENECTOMY; T LYMPHOCYTE;

ADULT; ANTIBODIES; B-LYMPHOCYTES; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SPLEEN; SPLENECTOMY; T-LYMPHOCYTES; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 84864716977     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182562881     Document Type: Review

References (24)

1. Rafiq MA, de Boccardo G, Schröppel B, et al. Differential outcomes in 3 types of acute antibody-mediated rejection. Clin Transplant 2009; 23(6): 951.
2. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2(8): 758.
3. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66(6): 800.
4. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-matchYpositive recipients. Transplantation 2000; 70(6): 887.
5. Warren DS, Zachary AA, Sonnenday CJ, et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004; 4(4): 561.
6. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76(10): 1519.
7. Venetz JP, Pascual M. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs 2007; 16(5): 625.
8. Kaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23(1): 63.
9. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359(3): 242.
10. Everly JJ, Walsh RC, Alloway RR, et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14(6): 662.
11. Kaplan B, Gangemi A, Thielke J, et al. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007; 83(1): 99.
12. Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7(4): 842.
13. Stegall MD, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9(5): 998.
14. Kaplan B, Jie T, Diana R, et al. Histopathology and immunophenotype of the spleen during acute antibody-mediated rejection. Am J Transplant 2010; 10(5): 1316.
15. Sanz I, Wei C, Lee FE, et al. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008; 20(1): 67.
16. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9(5): 1099.
17. Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90(12): 1486.
18. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9(1): 201.
19. Waiser J, Budde K, Schütz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant 2011; 27(3): 1246.
20. Magee CC. Transplantation across previously incompatible immunological barriers. Transpl Int 2006; 19(2): 87.
21. Thielke JJ, West-Thielke PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009; 87(2): 268.
22. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.
23. Racusen LC, Solez K, Colvin RB et al. The Banff 097 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
24. Solez K, Colvin RB, Racusen LC, et al. Meeting report Banff 07 classification of renal allograft pathology: updates and future direction. Am J Transplant 2008; 8: 753.